

# NULISAseq™ CNS Disease Panel 120

## Comprehensive Profiling of CNS Diseases at the Lowest Limit of Detection



The identification of clinically relevant biomarkers for neurodegenerative disorders is critical to the development of better therapeutic options and improved patient outcomes. Highly sensitive, multiplexed analysis of both neuro-specific proteins and the inflammatory response from blood and CSF provides scientists the

power to detect important biomarkers such as pTau217, GFAP and NFL, as well as measure changes in the key hallmarks of CNS disease. The NULISAseq CNS Disease Panel 120 provides robust analysis of 120+ proteins using just 25µL of sample input to support biomarker discovery and validation studies.

- Alzheimer's Disease
- Parkinson's Disease
- Huntington's Disease
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Traumatic Brain Injury
- Prion Disease
- Brain Cancers


### Discover more with broadest coverage of CNS Biology

>120 targets with >90% detectability in plasma




### Ultra-high sensitivity

Detect key low abundant biomarkers such as pTau217, GFAP and NFL with attomolar (fg/mL) sensitivity.





### ~12 logs dynamic range

Measure protein changes across a broad range of biological expression levels with up to 12 logs dynamic range in a single sample without dilution.



### Median CVs <10% guarantees high reproducibility

Confidence in your results with highly reproducible assays with median CVs <10%.



Read and cite the latest NULISA publication in *Nature Communications*.



# NULISAseq™ CNS Disease Panel 120

Comprehensive analysis of 120+ biomarkers across major hallmarks in CNS Disease

AMYLOID & TAU PATHOLOGIES			SYNUCLEIN & SYNAPTIC			VASCULAR & METABOLISM	
Abeta38 (aβ38)	BACE1	PSEN1	AGRN	IL6R (IL6Rα)	SNCB (β-Syn)	FLT1 (VEGF R1)	PGK1
Abeta40 (aβ40)	BASP1	pTau181	ARSA	MDH1	SOD1	HBA1; HBA2	POSTN
Abeta42 (aβ42)	CD63	pTau217	BDNF	NGF	TDP43	KDR (VEGF R2)	PTN
ACHE	CST3	pTau231	DDC	Oligo-SNCA (Oligo-α-Syn)	pTDP43-409	MME	SAA1
APOE	IGFBP7	SFRP1	FABP3	PARK7	UCHL1	PDGFRB	VEGF-A
APOE (APOE4)	KLK6	tTau(totalTau)	FOLR1	pSNCA-129	VEGF	PGF(PLGF)	VEGF-D
			HTT	SNCA (α-Syn)	VSNL1 (VILIP-1)		

NEURODEGENERATION		INFLAMMATION			
ANXA5	NPTX2	CCL2 (MCP1)	CSF2 (GM-CSF)	IL4	PRDX6
CALB2	NPTXR	CCL3 (MIP1a/CCL3)	CX3CL1 (Fractalkine)	IL5	RUVBL2
CNTN2	NPY	CCL4 (Mip1b/CCL4)	CXCL1 (GROα)	IL6	S100A12
ENO2	NRGN	CCL11 (Eotaxin)	CXCL8 (IL8)	IL7	S100B
FGF2 (FGF basic)	PDLIM5	CCL13 (MCP4)	CXCL10 (IP-10)	IL9	SFTPD
GDI1	REST	CCL17 (TARC/CCL17)	FCN2	IL10	SLIT2
GDNF	SMOC1	CCL22 (MDC)	GDF15	IL12A IL12B (IL-12p70)	TAFA5
GOT1	SNAP25	CCL26 (Eotaxin-3)	GFAP	IL13	TEK (Tie-2/TEK)
MSLN	SQSTM1	CD40LG (CD40L/TNFSF5)	ICAM1	IL15	TIMP3
NEFH	UBB	CHI3L1 (YKL40)	IFNG (IFN-gamma)	IL16	TNF (TNF-a)
NFL	YWHAG	CHIT1	IGF1R	IL17A	TREM1 (sTREM1)
NPTX1	YWHAZ	CRH	IL1B(IL-1 beta)	IL18	TREM2
		CRP	IL2	IL33	VCAM1(CD106)



**Brought to you by Sapient, an Alamar Certified Service Provider for NULISA™ panels and assays**

Sapient leverages Alamar's technologies to support protein biomarker discovery and validation for your CNS studies. Trust our proven expertise in high-sensitivity multiplexing of cytokines, chemokines, and neuroinflammatory mediators for rapid, reproducible results to inform your drug development – and learn how we can integrate these findings with other proteomics and multi-omics data for rich insights.

**Request services: [sapient.bio/nulisa](https://sapient.bio/nulisa) | [discover@sapient.bio](mailto:discover@sapient.bio) | 858.290.7010**

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

©2025 Alamar Biosciences, Inc. All rights reserved. Alamar, NULISA, NULISAseq and ARG0 are trademarks of Alamar Biosciences, Inc. All other trademarks and/or service marks not owned by Alamar that appear are the property of their respective owners. M1004-1024

